Claims for Patent: 7,608,643

Summary for Patent: 7,608,643

Title:	Compounds for inhibiting KSP kinesin activity
Abstract:	The present invention relates to compounds of Formula I or pharmaceutically acceptable salts or solvates thereof: ##STR00001## The present invention provides compositions comprising these compounds that are useful for treating cellular proliferative diseases or disorders associated with KSP kinesin activity and for inhibiting KSP kinesin activity.
Inventor(s):	Doll; Ronald J. (Convent Station, NJ), Herbst; Ronald (Palo Alto, CA), Seghezzi; Wolfgang (Mountain View, CA), Lees; Emma M. (Oakland, CA), Estacio; William F. (San Lorenzo, CA)
Assignee:	Schering Corporation (Kenilworth, NJ)
Application Number:	11/370,005
Patent Claims:	1. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, adjuvant or vehicle: ##STR00006## 2. The composition of claim 1, wherein the compound is the (+)-enantiomer of ##STR00007## or a pharmaceutically acceptable salt thereof. 3. The composition of claim 1, wherein the compound is the (-)-enantiomer of ##STR00008## or a pharmaceutically acceptable salt thereof. 4. The pharmaceutical composition of claim 1, further comprising one or more compounds selected from the group consisting of an anti-cancer agent, a PPAR-.gamma. agonist, a PPAR-.delta. agonist, an inhibitor of inherent multidrug resistance, an anti-emetic agent, and an immunologic-enhancing drug. 5. The pharmaceutical composition of claim 4, wherein the anti-cancer agent is selected from the group consisting of an estrogen receptor modulator, an androgen receptor modulator, retinoid receptor modulator, a cytotoxic/cytostatic agent, an antiproliferative agent, a prenyl-protein transferase inhibitor, an HMG-CoA reductase inhibitor, an angiogenesis inhibitor, an inhibitor of cell proliferation and survival signaling, an agent that interferes with a cell cycle checkpoint, and an apoptosis inducing agent. 6. The pharmaceutical composition of claim 4, further comprising one or more anti-cancer agents selected from the group consisting of cytostatic agents, cytotoxic agents, taxanes, topoisomerase II inhibitors, topoisomerase I inhibitors, tubulin interacting agents, hormonal agents, thymidilate synthase inhibitors, anti-metabolites, alkylating agents, farnesyl protein transferase inhibitors, signal transduction inhibitors, EGER kinase inhibitors, antibodies to EGER, C-abl kinase inhibitors, hormonal therapy combinations, and aromatase combinations. 7. The pharmaceutical composition of claim 4, further comprising one or more agents selected from the group consisting of Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, oxaliplatin, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17.alpha.-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methyipred nisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethyl melamine, doxorubicin, cyclophosphamide, gemcitabine, interferons, pegylated interferons, Erbitux and mixtures thereof.

Details for Patent 7,608,643

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2025-03-09
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2025-03-09
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2025-03-09